JP2023123502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023123502A5 JP2023123502A5 JP2023093016A JP2023093016A JP2023123502A5 JP 2023123502 A5 JP2023123502 A5 JP 2023123502A5 JP 2023093016 A JP2023093016 A JP 2023093016A JP 2023093016 A JP2023093016 A JP 2023093016A JP 2023123502 A5 JP2023123502 A5 JP 2023123502A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- sequence shown
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000005754 cellular signaling Effects 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671193P | 2018-05-14 | 2018-05-14 | |
| US62/671,193 | 2018-05-14 | ||
| PCT/US2019/031983 WO2019222082A1 (en) | 2018-05-14 | 2019-05-13 | Anti-cd24 compositions and uses thereof |
| JP2020564389A JP7294758B2 (ja) | 2018-05-14 | 2019-05-13 | 抗ｃｄ２４組成物及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564389A Division JP7294758B2 (ja) | 2018-05-14 | 2019-05-13 | 抗ｃｄ２４組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023123502A JP2023123502A (ja) | 2023-09-05 |
| JP2023123502A5 true JP2023123502A5 (enExample) | 2024-03-19 |
| JP7662707B2 JP7662707B2 (ja) | 2025-04-15 |
Family
ID=68540727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564389A Active JP7294758B2 (ja) | 2018-05-14 | 2019-05-13 | 抗ｃｄ２４組成物及びその使用 |
| JP2023093016A Active JP7662707B2 (ja) | 2018-05-14 | 2023-06-06 | 抗ｃｄ２４組成物及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564389A Active JP7294758B2 (ja) | 2018-05-14 | 2019-05-13 | 抗ｃｄ２４組成物及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US12286485B2 (enExample) |
| EP (1) | EP3813877A4 (enExample) |
| JP (2) | JP7294758B2 (enExample) |
| KR (2) | KR20250122537A (enExample) |
| CN (2) | CN112424441B (enExample) |
| AU (2) | AU2019269361C1 (enExample) |
| BR (1) | BR112020022482A2 (enExample) |
| CA (1) | CA3099554A1 (enExample) |
| EA (1) | EA202092306A1 (enExample) |
| MX (3) | MX2020012091A (enExample) |
| SG (1) | SG11202010589YA (enExample) |
| TW (1) | TWI835794B (enExample) |
| WO (1) | WO2019222082A1 (enExample) |
| ZA (1) | ZA202006647B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2020261280A1 (en) * | 2019-06-25 | 2020-12-30 | Ichilov Tech Ltd. | Anti-cd24 antibody and uses thereof |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CA3210934A1 (en) * | 2021-02-08 | 2022-08-11 | Antengene Biologics Limited | Novel anti-cd24 antibodies |
| CA3208891A1 (en) * | 2021-02-18 | 2022-08-25 | Leonid CHERKASSKY | Antibody-derived t cell activating technologies |
| WO2023280042A1 (zh) * | 2021-07-06 | 2023-01-12 | 盛禾(中国)生物制药有限公司 | 一种抗cd24抗体及其应用 |
| CN118076625A (zh) * | 2021-09-28 | 2024-05-24 | 广州昂科免疫生物技术有限公司 | 包含071核心肽的融合蛋白及其用途 |
| CN113831412B (zh) * | 2021-10-13 | 2023-06-20 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd24的抗体及其制备和用途 |
| US20250320309A1 (en) * | 2021-11-25 | 2025-10-16 | Shenghe (China) Biopharmaceutical Co., Ltd. | Bispecific antigen binding protein |
| US20250263500A1 (en) * | 2021-12-07 | 2025-08-21 | Beijing Kanghong Biomedical Co., Ltd | Anti-cd24 antibody and use thereof |
| CN115947855B (zh) * | 2022-05-20 | 2023-10-27 | 杭州邦顺制药有限公司 | 抗cd24抗体的制备及其用途 |
| EP4608868A1 (en) * | 2022-10-27 | 2025-09-03 | Beijing Neox Biotech Limited | Antibodies against cd24 and uses thereof |
| EP4613779A1 (en) * | 2022-11-01 | 2025-09-10 | Acroimmune Biopharma Co., Ltd. | Cd24 binding protein and use thereof |
| CN115960243B (zh) * | 2023-01-09 | 2025-05-06 | 中国药科大学 | 靶向cd24和cd3的双特异性抗体及其应用 |
| WO2024251257A1 (en) * | 2023-06-09 | 2024-12-12 | TJ Biopharma (Shanghai) Co., Ltd. | Anti-cd24 antibodies and uses thereof |
| KR20250049518A (ko) * | 2023-10-04 | 2025-04-11 | 재단법인대구경북과학기술원 | 항-cd24 항체 또는 이의 항원 결합 단편 및 이의 용도 |
| CN119823282A (zh) * | 2023-10-12 | 2025-04-15 | 江苏融泰生物技术有限公司 | 抗体融合蛋白及应用 |
| WO2025085805A1 (en) * | 2023-10-20 | 2025-04-24 | OncoC4, Inc. | Anti-cd24/anti-cd3 bispecific binding proteins and uses thereof |
| WO2025101970A1 (en) * | 2023-11-08 | 2025-05-15 | Pheast Therapeutics, Inc. | Cd24 antibodies |
| WO2025151423A1 (en) * | 2024-01-08 | 2025-07-17 | OncoC4, Inc. | Anti-cd24 antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022597A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| CN1894413A (zh) * | 2003-03-26 | 2007-01-10 | 特鲁比昂药品公司 | 识别cd3或4－1bb的抗体或基因介导的肿瘤反应性淋巴细胞活化 |
| US8614301B2 (en) | 2007-11-14 | 2013-12-24 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of treating cancer using anti CD24 antibodies |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| WO2011139820A1 (en) * | 2010-04-28 | 2011-11-10 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| EP2574627A1 (en) * | 2011-09-30 | 2013-04-03 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Particular uses of CD24 inhibitors |
| JP6571527B2 (ja) * | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． | 二重特異性抗体 |
| WO2015058048A1 (en) | 2013-10-18 | 2015-04-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| CN103819561A (zh) | 2014-01-22 | 2014-05-28 | 中国药科大学 | 抗cd24单克隆抗体、其可变区序列及其应用 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| US9804170B2 (en) * | 2015-02-09 | 2017-10-31 | Bristol-Myers Squibb Company | Antibodies to polyethylene glycol |
| US20210198368A1 (en) | 2016-01-21 | 2021-07-01 | Novartis Ag | Multispecific molecules targeting cll-1 |
-
2019
- 2019-05-13 AU AU2019269361A patent/AU2019269361C1/en active Active
- 2019-05-13 WO PCT/US2019/031983 patent/WO2019222082A1/en not_active Ceased
- 2019-05-13 CN CN201980032893.9A patent/CN112424441B/zh active Active
- 2019-05-13 KR KR1020257026199A patent/KR20250122537A/ko active Pending
- 2019-05-13 EP EP19803135.3A patent/EP3813877A4/en active Pending
- 2019-05-13 KR KR1020207033131A patent/KR102844265B1/ko active Active
- 2019-05-13 MX MX2020012091A patent/MX2020012091A/es unknown
- 2019-05-13 TW TW108116423A patent/TWI835794B/zh active
- 2019-05-13 JP JP2020564389A patent/JP7294758B2/ja active Active
- 2019-05-13 SG SG11202010589YA patent/SG11202010589YA/en unknown
- 2019-05-13 EA EA202092306A patent/EA202092306A1/ru unknown
- 2019-05-13 BR BR112020022482-0A patent/BR112020022482A2/pt active Search and Examination
- 2019-05-13 US US17/055,248 patent/US12286485B2/en active Active
- 2019-05-13 CN CN202310460291.1A patent/CN116589582A/zh active Pending
- 2019-05-13 CA CA3099554A patent/CA3099554A1/en active Pending
-
2020
- 2020-10-26 ZA ZA2020/06647A patent/ZA202006647B/en unknown
- 2020-11-11 MX MX2025002661A patent/MX2025002661A/es unknown
- 2020-11-11 MX MX2024015039A patent/MX2024015039A/es unknown
-
2023
- 2023-06-06 JP JP2023093016A patent/JP7662707B2/ja active Active
-
2025
- 2025-03-14 AU AU2025201864A patent/AU2025201864A1/en active Pending
- 2025-04-03 US US19/169,938 patent/US20250333532A1/en active Pending
- 2025-04-03 US US19/169,932 patent/US20250243292A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023123502A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP2018525033A5 (enExample) | ||
| RU2355705C2 (ru) | Одноцепочечное цикличное триспецифическое антитело | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| JP2024023228A5 (enExample) | ||
| JP2021106605A5 (enExample) | ||
| RU2020120853A (ru) | Мультиспецифичные химерные рецепторы, содержащие домен nkg2d, и способы их применения | |
| JP2015527070A5 (enExample) | ||
| JP2020530989A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| JP2019527557A5 (enExample) | ||
| BR112017002422B1 (pt) | Domínio de ligação a cd3 | |
| JPWO2020160050A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2019530431A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| JP2018521628A5 (enExample) | ||
| JP2024508672A (ja) | 新規抗ｃｄ２４抗体 | |
| JPWO2019191120A5 (enExample) | ||
| JPWO2019005637A5 (enExample) | ||
| JPWO2021184673A5 (enExample) | ||
| JP2019505545A5 (enExample) | ||
| JPWO2019005640A5 (enExample) | ||
| US12005082B2 (en) | Composition and method of use recombinant fusion protein to generate CAR-immune cells |